Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.63 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.62 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.56 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.53 |
| ▸ | GAPDH | P04406 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480564 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL1692159 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL19668574 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL3299698 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL2346223 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL3302874 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL1691709 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| SCHEMBL12102087 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL3408493 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 | |
| Lipoxin A4 SCHEMBL8743448 | 1.00 | FPR2 (1.00) | FPR2NFKB1NFKB2RELALTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266005-B1 | REGULATION OF HUMAN LIPOXIN A4 RECEPTOR-LIKE PROTEIN | BAYER HEALTHCARE AG (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-20030060512-A1 | Modulation of inflammation related to columnar epithelia | MADARA JAMES L (US) | 2003-03-27 | — | — | US | disclosed |
| EP-1266005-A2 | REGULATION OF HUMAN LIPOXIN A4 RECEPTOR-LIKE PROTEIN | Bayer Aktiengesellschaft (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-20020058259-A1 | Regulation of human lipoxin A4 receptor-like protein | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-16 | — | — | US | disclosed |
| WO-2001068839-A2 | REGULATION OF HUMAN LIPOXIN A4 RECEPTOR-LIKE PROTEIN | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| EP-0469075-B1 | USE OF LIPOXIN A 4? AND ITS DERIVATIVES AS ANTAGONISTS FOR SLOW-REACTING SUBSTANCES OF ANAPHYLAXIS | BRIGHAM & WOMENS HOSPITAL (US) | 1997-01-08 | — | — | EP | disclosed |
| EP-0469075-A4 | USE OF LIPOXIN A 4? AND ITS DERIVATIVES AS ANTAGONISTS FOR SLOW-REACTING SUBSTANCES OF ANAPHYLAXIS | — | 1992-09-09 | — | — | EP | disclosed |
| EP-0469075-A1 | USE OF LIPOXIN A 4? AND ITS DERIVATIVES AS ANTAGONISTS FOR SLOW-REACTING SUBSTANCES OF ANAPHYLAXIS. | BRIGHAM & WOMENS HOSPITAL (US) | 1992-02-05 | — | — | EP | disclosed |
| US-5079261-A | USE OF LIPOXIN A4 AND ITS DERIVATIVES AS ANTAGONISTS FOR SLOW-REACTING SUBSTANCES OF ANAPHYLAXIS | BRIGHAM AND WOMEN'S HOSPITAL | 1992-01-07 | — | — | US | disclosed |
| WO-1990013292-A1 | USE OF LIPOXIN A4 AND ITS DERIVATIVES AS ANTAGONISTS FOR SLOW-REACTING SUBSTANCES OF ANAPHYLAXIS | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060512-A1 | Modulation of inflammation related to columnar epithelia | LTB4R2, ALOX15B, LTB4R | FPR2 43/4885NFKB1 414/4885NFKB2 380/4885 |
| US-20020058259-A1 | Regulation of human lipoxin A4 receptor-like protein | LTB4R, LTA4H, LTB4R2 | FPR2 139/4885NFKB1 2802/4885NFKB2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.